Chen Jingtao, Niu Chao, Yang Ning, Liu Chunyan, Zou Shan-Shan, Zhu Shan
Cancer Center, The First Hospital of Jilin University, Changchun 130021, China; Laboratory for Tumor Immunology, The First Hospital of Jilin University, Changchun 130021, China.
Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Pharmacol Res. 2023 Mar;189:106674. doi: 10.1016/j.phrs.2023.106674. Epub 2023 Jan 23.
Liver cancer is one of the most common malignancies, with severe morbidity and mortality. While considerable progress has been made in liver cancer treatment, the 5-year overall survival (OS) of patients has not improved significantly. Reasons include the inadequate capability of early screening and diagnosis, a high incidence of recurrence and metastasis, a high degree of tumor heterogeneity, and an immunosuppressive tumor microenvironment. Therefore, the identification and validation of specific and robust liver cancer biomarkers are of major importance for early screening, timely diagnosis, accurate prognosis, and the prevention of tumor progression. In this review, we highlight some of the latest research progress and potential applications of liver cancer biomarkers, describing hotspots and prospective directions in biomarker discovery.
肝癌是最常见的恶性肿瘤之一,具有严重的发病率和死亡率。虽然肝癌治疗已取得相当大的进展,但患者的5年总生存率并未显著提高。原因包括早期筛查和诊断能力不足、复发和转移发生率高、肿瘤异质性程度高以及免疫抑制性肿瘤微环境。因此,识别和验证特异性强且可靠的肝癌生物标志物对于早期筛查、及时诊断、准确预后以及预防肿瘤进展至关重要。在本综述中,我们重点介绍了肝癌生物标志物的一些最新研究进展和潜在应用,描述了生物标志物发现的热点和未来方向。